Replimune Group Inc (REPL) is a biotechnology company that focuses on developing and commercializing oncolytic immunotherapies for the treatment of various cancers. In order to assess the performance of REPL stock, technical analysis can be conducted using different indicators. These indicators provide insights into the current trend and momentum of the stock.

One important technical indicator is the Relative Strength Index (RSI), which measures the speed and change of price movements. A high RSI indicates overbought conditions, while a low RSI suggests oversold conditions. Another useful indicator is the Average Directional Index (ADX), which measures the strength of the current trend. A high ADX value indicates a strong trend, while a low value suggests a weak trend.

Replimune Group  (REPL) Technical Analysis

Learn about the technical analysis indicators for Replimune Group Inc (REPL) stock, including RSI, ADX, MACD, and ROC. Explore the stock's STOCHRSI and WILLR values. Find out the technical analysis rating for REPL based on these indicators.

Replimune Group Inc (REPL) Technical Analysis: Indicators, RSI, ADX, MACD, and More

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Replimune Group 

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	68.90	Neutral	19.7%
auto_graphMACD	33.21	Neutral	955.9%
auto_graphCCI	181.61	Sell	261.4%
auto_graphADX	31.96	Neutral	-
auto_graphATR	65.18	Buy	-
auto_graphWILLR	-21.43	Neutral	331.4%
auto_graphROC	132.99	Neutral	609.7%
auto_graphSTOCHRSI	92.29	Sell	103.7%

Buy	1	-87.50%
Hold	5	-37.50%
Sell	2	-75.00%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Replimune Group (REPL) Technical Analysis

Keep an eye on Replimune Group

Frequently Asked Questions

What are the technical signals for Replimune Group (REPL) stock based on the last 30 days?

Take Your Investments to a Whole New Level